China Urges US to Halt Wider Investment Curbs Plan

The US China investment curbs dispute flared again on Saturday, as Beijing urged Washington to stop expanding restrictions on American investments in China, calling a new Treasury proposal discriminatory and damaging to bilateral trade ties.

China’s commerce ministry said in a statement that the proposed rule would widen curbs on sensitive technologies, disrupt trade ties and run counter to the consensus reached by the two countries’ presidents, who have met twice in the past six months.

The U.S. Treasury Department issued proposals on Thursday to update its outbound-investment security program, adding biotechnology to restricted sectors and expanding coverage of high-performance computing and hypersonic systems, according to Reuters.

What the new proposal covers

The outbound-investment program restricts certain U.S. investments involving China in sectors deemed sensitive to national security. It already covered semiconductors, quantum technologies and artificial intelligence.

Under the Treasury’s proposed update, the program would expand in several ways:

• Biotechnology would be added as a restricted sector
• Coverage of high-performance computing would be expanded
• Hypersonic systems would fall under broader restrictions

The Treasury has said the measures, which do not only cover China, are intended to stop U.S. capital from supporting foreign adversaries’ development of dual-use strategic technologies that could threaten U.S. national security.

Dual-use technologies are those with both civilian and military applications — a category that has grown steadily as advances in computing, biology and materials science blur the line between commercial research and defense capability.

Beijing’s response

China’s commerce ministry said the proposal “discriminatorily” widened China-related investment restrictions and intensified curbs. Beijing said it firmly opposed the expansion and reserved the right to take unspecified countermeasures.

The ministry also argued that the move damaged bilateral economic ties and contradicted the understanding reached between the two presidents in their recent meetings. That framing matters: both sides have spent much of 2026 trying to stabilize a relationship marked by tariff wars, technology restrictions and strategic rivalry, and each new restriction tests how durable that stabilization really is.

Chinese officials have consistently argued that U.S. investment restrictions are overbroad and harm legitimate commercial activity. U.S. officials counter that the restrictions are narrowly targeted at technologies with clear military applications and that American investors should not be funding capabilities that could be used against the United States.

Why biotechnology is the flashpoint

Adding biotechnology to the restricted list is the most consequential part of the proposal. Biotech spans drug discovery, genomics, agricultural science and industrial biology — fields where U.S. and Chinese researchers and companies have deep commercial ties.

Investors worry that broad restrictions could chill funding for legitimate medical and agricultural research, while security officials argue that advances in biotechnology, including gene editing and pathogen research, carry risks that justify controls.

The same tension applies to high-performance computing and hypersonics. Supercomputers power everything from weather forecasting to weapons design, and hypersonic systems — missiles that travel at more than five times the speed of sound — are a central focus of military competition between the two countries.

For companies, the practical question is how the rules are written. Narrow, clearly defined restrictions are easier to comply with; broad or vague ones can freeze investment across entire sectors as firms steer clear of anything that might fall under the rules.

The wider technology standoff

The investment curbs are one piece of a much larger technology standoff. Over the past several years, the United States has restricted exports of advanced semiconductors and chip-making equipment to China, limited Chinese access to certain software and cloud services, and screened Chinese investments in the United States.

China has responded with its own export controls on critical minerals, restrictions on some technology transfers and support for domestic champions in semiconductors, AI and biotechnology.

Each round of restrictions raises the same question: where is the line between protecting national security and decoupling two economies that remain deeply intertwined? American companies still sell heavily into China, Chinese firms still supply components and materials to U.S. manufacturers, and researchers in both countries still collaborate.

The Treasury proposal is still at the proposal stage, which means there will be a period for public comment and revision before any final rule takes effect. Industry groups, investors and academics are expected to weigh in, and the final version may look different from the draft.

What to watch next

Several developments will shape how this dispute plays out. First, the comment process will reveal how strongly U.S. industry pushes back against the biotechnology addition. Second, Beijing’s threat of countermeasures will be tested — whether it takes concrete steps or holds its response in reserve for leverage in future negotiations.

Third, the dispute will be read against the broader state of U.S.-China relations. The two presidents have met twice in six months, and both sides have signaled a desire to avoid a full economic rupture. A major escalation on investment rules would sit uneasily with that message.

For now, the proposal adds another layer of uncertainty for investors caught between the world’s two largest economies — a reminder that in the technology rivalry, the rules of the game are still being written, and they can change with a single Treasury notice.